Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples

Rhea-AI Summary

Mainz Biomed (NASDAQ: MYNZ) will present clinical poster data at Digestive Disease Week 2026 in Chicago on Feb 24, 2026. The poster reports a blood-based mRNA signature for pancreatic cancer with reported 100% sensitivity and 95% specificity.

The presentation, titled “BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS,” highlights the company’s discovery-study results and potential for early-stage detection.

News Market Reaction – MYNZ

+3.45%

6 alerts

+3.45% News Effect

+17.0% Peak Tracked

-2.1% Trough Tracked

+$198K Valuation Impact

$6M Market Cap

0.3x Rel. Volume

On the day this news was published, MYNZ gained 3.45%, reflecting a moderate positive market reaction. Argus tracked a peak move of +17.0% during that session. Argus tracked a trough of -2.1% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $198K to the company's valuation, bringing the market cap to $6M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Sensitivity: 100% Specificity: 95%

2 metrics

Sensitivity 100% Pancreatic cancer blood-based mRNA biomarker results presented at DDW 2026

Specificity 95% Pancreatic cancer blood-based mRNA biomarker results presented at DDW 2026

Market Reality Check

Price: $0.7368 Vol: Volume 124,090 is only 0....

low vol

$0.7368 Last Close

Volume Volume 124,090 is only 0.17x the 20-day average of 724,241, indicating limited pre-news participation. low

Technical Shares at 0.5916 are trading below the 200-day MA of 1.51 and sit 90.59% below the 52-week high, near the 52-week low.

Peers on Argus

MYNZ was down 2.97% while momentum peers were mixed: NDRA up 2.93%, NOTV up 2.52...

2 Up 1 Down

MYNZ was down 2.97% while momentum peers were mixed: NDRA up 2.93%, NOTV up 2.52%, and ISPC down 3.73%. Only one peer moved in the same (down) direction, pointing to a stock-specific move rather than a sector-wide trend.

Historical Context

5 past events · Latest: Feb 17 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Dilutive financing	Negative	-15.6%	$6M private placement and strategic pivot tied to preferred stock deal.
Jan 14	Clinical presentation	Positive	+0.0%	Planned AACR 2026 presentation on blood-based mRNA signature for PDAC detection.
Jan 05	Program update	Positive	+9.5%	Review of 2025 highlights including strong CRC and pancreatic program data.
Dec 02	Commercial partnership	Positive	+2.6%	ColoAlert added to DoctorBox digital health platform for broader German access.
Nov 18	Geographic expansion	Positive	-4.8%	MOU with OncoVanguard8 to introduce ColoAlert in initial South American markets.

Pattern Detected

Recent news often produced aligned reactions: funding and highly dilutive financing drew selling, while positive clinical and commercial updates more often saw modest gains, though some positive items drew muted or negative moves.

Recent Company History

Over the last few months, Mainz Biomed has balanced financing needs with clinical and commercial progress. A $6.0 million private placement and highly dilutive preferred stock financing on Feb 17, 2026 coincided with a -15.58% move. Earlier, 2025 highlights featuring strong colorectal and pancreatic data and new partnerships led to reactions from +9.48% to modest gains. Today’s pancreatic biomarker presentation at DDW extends the theme of advancing its blood-based detection platform within an already pressured share price context.

Regulatory & Risk Context

Active S-3 Shelf · $150,000,000

Shelf Active

Active S-3 Shelf Registration 2025-12-05

$150,000,000 registered capacity

An effective Form F-3 shelf filed on Dec 5, 2025 allows Mainz Biomed to offer up to $150,000,000 of ordinary shares, preferred shares, warrants and units subject to Form F‑3 limits. The shelf is not yet effective and shows 0 recorded usages in the provided data.

Market Pulse Summary

This announcement highlights blood-based pancreatic cancer detection data with 100% sensitivity and ...

Analysis

This announcement highlights blood-based pancreatic cancer detection data with 100% sensitivity and 95% specificity, reinforcing Mainz Biomed’s focus on mRNA biomarker-driven diagnostics. It follows prior updates on its colorectal and pancreatic programs and recent financings that reshape the capital structure. Investors may watch for larger, confirmatory studies, regulatory pathways, partnering activity, and any future use of the registered $150,000,000 shelf as key markers of execution and dilution risk.

Key Terms

mRNA, pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasms, biomarker

4 terms

mRNA medical

"Industry Leading Results: 100% Sensitivity and 95% Specificity... BLOOD-BASED MRNA SIGNATURE"

mRNA, short for messenger ribonucleic acid, is a biological molecule that carries instructions from a cell’s genetic blueprint to make specific proteins — like a recipe or software code that tells a kitchen or computer what to produce. Investors care because mRNA is used as a flexible drug and vaccine platform that can be developed and scaled faster than many traditional medicines; its commercial prospects, manufacturing needs, regulatory approval path, and patent position can strongly affect a company’s value.

pancreatic ductal adenocarcinoma medical

"BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION"

A fast-growing cancer that starts in the cells lining the pancreas’ small ducts; it is the most common and aggressive form of pancreatic cancer. It matters to investors because its severity and limited treatment options drive high unmet medical need, large potential markets for effective drugs or diagnostics, and strong sensitivity of company valuations to clinical trial results, regulatory approvals, or changes in treatment guidelines—similar to how fixing a main leak can prevent major damage in a building.

intraductal papillary mucinous neoplasms medical

"DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS"

Noncancerous or pre-cancerous growths that form in the mucus-producing ducts of the pancreas; they can stay harmless or develop into pancreatic cancer over time, so doctors monitor them closely. Think of them like corrosion inside a pipe: small spots may be watched, but if they start spreading or causing blockage, they require repair. For investors, their presence drives demand for diagnostic tests, drugs, and surgical or imaging technologies, influences clinical trial design and regulatory decisions, and shapes market opportunities and health-care costs related to pancreatic disease.

biomarker medical

"our algorithm and biomarker selection can identify neoplasms in blood."

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

AI-generated analysis. Not financial advice.

Mainz Biomed to Present Industry Leading Results: 100% Sensitivity and 95% Specificity

BERKELEY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the renowned Digestive Disease Week (DDW) 2026 in Chicago, Illinois. At the conference the Company will present its poster titled “BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS”.

“We are thrilled about the team’s progress in confirming the strong clinical results from our discovery study. What’s particularly exciting is that our algorithm and biomarker selection can identify neoplasms in blood. Delivering a blood-based test capable of detecting early stages of disease is major step toward the early detection—and ultimately the elimination—of pancreatic cancer,” said Guido Baechler, CEO Mainz Biomed

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Mainz Biomed NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. Mainz Biomed’s product candidate portfolio is focused on PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.

For investor inquiries, please contact ir@mainzbiomed.com 

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

FAQ

What did Mainz Biomed (MYNZ) report at Digestive Disease Week 2026 about pancreatic cancer detection?

They reported a blood-based mRNA signature with 100% sensitivity and 95% specificity for detecting pancreatic neoplasms. According to the company, this result comes from their discovery study and will be presented in a poster at DDW 2026.

When and where will Mainz Biomed (MYNZ) present its DDW 2026 poster on Feb 24, 2026?

Mainz Biomed will present its poster at Digestive Disease Week 2026 in Chicago on Feb 24, 2026. According to the company, the poster session will detail the blood-based mRNA signature and study findings.

What is the title of Mainz Biomed's (MYNZ) DDW 2026 poster and what does it study?

The poster is titled “BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS.” According to the company, it studies an mRNA biomarker algorithm for blood detection of pancreatic neoplasms.

How might Mainz Biomed's (MYNZ) blood-based test affect early detection of pancreatic cancer?

The company suggests the blood-based mRNA test could enable earlier detection of pancreatic neoplasms, improving diagnostic timing. According to Mainz Biomed, the algorithm and biomarkers identified in their discovery study support this potential benefit.

Are Mainz Biomed's (MYNZ) DDW 2026 results final clinical validation or discovery-stage findings?

These results are described as findings from the company’s discovery study rather than full clinical validation. According to Mainz Biomed, the poster confirms strong clinical results from their discovery-stage work.

Where can investors find more information about Mainz Biomed (MYNZ) and the DDW 2026 presentation?

Investors can visit Mainz Biomed’s investor website for details and updates on the DDW 2026 poster and company developments. According to the company, additional information is available at mainzbiomed.com/investors/.